JP2019532672A - 多孔質膜系巨大分子送達システム - Google Patents

多孔質膜系巨大分子送達システム Download PDF

Info

Publication number
JP2019532672A
JP2019532672A JP2019538110A JP2019538110A JP2019532672A JP 2019532672 A JP2019532672 A JP 2019532672A JP 2019538110 A JP2019538110 A JP 2019538110A JP 2019538110 A JP2019538110 A JP 2019538110A JP 2019532672 A JP2019532672 A JP 2019532672A
Authority
JP
Japan
Prior art keywords
cells
cell
microns
pores
membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019538110A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019532672A5 (enExample
Inventor
ファチン，ファビオ
フィオリノ，マイケル
リー，キャメロン
ヤン，イ
イェン，ジョナサン
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2019532672A publication Critical patent/JP2019532672A/ja
Publication of JP2019532672A5 publication Critical patent/JP2019532672A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2019538110A 2016-09-28 2017-09-28 多孔質膜系巨大分子送達システム Pending JP2019532672A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662401053P 2016-09-28 2016-09-28
US62/401,053 2016-09-28
PCT/US2017/054110 WO2018064387A1 (en) 2016-09-28 2017-09-28 Porous membrane-based macromolecule delivery system

Publications (2)

Publication Number Publication Date
JP2019532672A true JP2019532672A (ja) 2019-11-14
JP2019532672A5 JP2019532672A5 (enExample) 2020-11-12

Family

ID=60183103

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019538110A Pending JP2019532672A (ja) 2016-09-28 2017-09-28 多孔質膜系巨大分子送達システム

Country Status (5)

Country Link
US (1) US20190203230A1 (enExample)
EP (1) EP3519577A1 (enExample)
JP (1) JP2019532672A (enExample)
CN (1) CN109844126A (enExample)
WO (1) WO2018064387A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9017991B2 (en) 2009-03-13 2015-04-28 Tufts University Methods tip assemblies and kits for introducing material into cells
CA2986310A1 (en) 2015-05-11 2016-11-17 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells
US11911415B2 (en) 2015-06-09 2024-02-27 Editas Medicine, Inc. CRISPR/Cas-related methods and compositions for improving transplantation
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
EP3652312A1 (en) 2017-07-14 2020-05-20 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
CN110272810A (zh) * 2019-07-01 2019-09-24 广州世赛生物科技有限公司 外源物质递送至真核细胞内的装置和方法及其应用
EP4337769A1 (en) * 2021-05-10 2024-03-20 SQZ Biotechnologies Company Methods for delivering genome editing molecules to the nucleus or cytosol of a cell and uses thereof
WO2024072514A1 (en) * 2022-09-30 2024-04-04 Xellar, Inc. Edge effect systems and methods for functionalized microfluidic devices
CN116297429B (zh) * 2023-03-14 2026-03-06 青岛农业大学 一种检测农药的比色传感器、其制备方法及应用
CN121399269A (zh) * 2023-05-15 2026-01-23 波特尔生物技术有限公司 基因编辑复合物及其组合的细胞递送

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016020616A1 (fr) * 2014-08-05 2016-02-11 Screencell Procédé pour le dépistage de la drépanocytose et kit pour sa mise en oeuvre
WO2017041050A1 (en) * 2015-09-04 2017-03-09 Sqz Biotechnologies Company Intracellular delivery of biomolecules mediated by a surface with pores

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7687267B2 (en) * 2006-09-30 2010-03-30 Rational Biotechnology Inc. High-throughput cell transfection device and methods of using thereof
US20110213288A1 (en) * 2007-04-23 2011-09-01 The Board Of Regents, The University Of Texas System Device And Method For Transfecting Cells For Therapeutic Uses
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
US20120244593A1 (en) * 2009-10-19 2012-09-27 Yong Huang Method, device and apparatus for inducing self-adjusting cell electroporation
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
GB2481983A (en) 2010-07-12 2012-01-18 Hart Fenton & Co Ltd A ship including a gas tank room
CA2805442C (en) 2010-07-21 2020-05-12 Sangamo Biosciences, Inc. Methods and compositions for modification of an hla locus
SI2807165T1 (sl) 2012-01-27 2019-08-30 Universite De Montreal Pirimido(4,5-B)indol derivati in njihova uporaba pri ekspanziji hematopoetskih matičnih celic
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
KR102955556B1 (ko) 2012-12-12 2026-04-22 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물
CN105209621B (zh) 2012-12-12 2021-05-25 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
SG11201505896YA (en) 2013-02-20 2015-09-29 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
WO2014130635A1 (en) 2013-02-20 2014-08-28 Novartis Ag Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
EP3004339B1 (en) 2013-05-29 2021-07-07 Cellectis New compact scaffold of cas9 in the type ii crispr system
WO2015048577A2 (en) 2013-09-27 2015-04-02 Editas Medicine, Inc. Crispr-related methods and compositions
ES2918501T3 (es) 2013-12-19 2022-07-18 Novartis Ag Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
US20170015994A1 (en) * 2014-02-24 2017-01-19 Massachusetts Institute Of Technology Methods for in vivo genome editing
CN122399016A (zh) 2014-03-15 2026-07-17 诺华股份有限公司 使用嵌合抗原受体治疗癌症
US10472651B2 (en) * 2014-03-28 2019-11-12 The Regents Of The University Of California Efficient delivery of large cargos into cells on a porous substrate
WO2015191693A2 (en) * 2014-06-10 2015-12-17 Massachusetts Institute Of Technology Method for gene editing
JP6831777B2 (ja) 2014-07-21 2021-02-17 ノバルティス アーゲー Ｃｄ３３キメラ抗原受容体を使用する癌の処置
BR112017000939A2 (pt) 2014-07-21 2017-11-14 Novartis Ag tratamento de câncer usando um receptor antigênico quimérico de cll-1
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
EP3712171A1 (en) 2014-08-19 2020-09-23 Novartis AG Treatment of cancer using a cd123 chimeric antigen receptor
CN122564053A (zh) * 2014-10-31 2026-08-14 麻省理工学院 递送生物分子至免疫细胞
WO2016094880A1 (en) * 2014-12-12 2016-06-16 The Broad Institute Inc. Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
AU2016206870B2 (en) * 2015-01-12 2022-02-17 Massachusetts Institute Of Technology Gene editing through microfluidic delivery
US20190024065A1 (en) * 2015-02-06 2019-01-24 Cellectis Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles
PL3280729T3 (pl) 2015-04-08 2022-08-22 Novartis Ag Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
WO2017093969A1 (en) 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology
MX2018007987A (es) 2015-12-28 2019-01-10 Novartis Ag Composiciones y metodos para el tratamiento de hemoglobinopatias.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016020616A1 (fr) * 2014-08-05 2016-02-11 Screencell Procédé pour le dépistage de la drépanocytose et kit pour sa mise en oeuvre
WO2017041050A1 (en) * 2015-09-04 2017-03-09 Sqz Biotechnologies Company Intracellular delivery of biomolecules mediated by a surface with pores

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BIOTECHNOLOGY AND BIOENGINEERING, vol. 65, no. 3, JPN6022019560, 5 November 1999 (1999-11-05), pages 341 - 346, ISSN: 0004947385 *

Also Published As

Publication number Publication date
CN109844126A (zh) 2019-06-04
EP3519577A1 (en) 2019-08-07
WO2018064387A1 (en) 2018-04-05
US20190203230A1 (en) 2019-07-04

Similar Documents

Publication Publication Date Title
US20190203230A1 (en) Porous membrane-based macromolecule delivery system
KR102752985B1 (ko) Vcar 조성물 및 사용 방법
Yen et al. TRIAMF: a new method for delivery of Cas9 ribonucleoprotein complex to human hematopoietic stem cells
JP7292213B2 (ja) Ｃｒｉｓｐｒ／ｃｐｆ１を用いる、ｔ細胞における遺伝子編集のための組成物および方法
CN107980059B (zh) 用于修饰基因组dna的方法和组合物
JP7428712B2 (ja) 低／最小操作による遺伝子改変細胞の製造
WO2019084552A1 (en) TARGETED REPLACEMENT OF ENDOGENIC T CELL RECEPTORS
US20200208111A1 (en) Genome-edited nk cell and methods of making and using
EP3245294A1 (en) Gene editing through microfluidic delivery
JP2016513974A (ja) 造血幹細胞系列を初期化するための組成物および方法
KR20220097985A (ko) Car-t 세포의 제조 방법
CN114729325A (zh) 在培养物中具有改善的持久性的基因工程化t细胞
EP4419672A2 (en) Compositions and methods for targeting, editing, or modifying genes
TW202016297A (zh) 抗藥性免疫細胞及使用其之方法
JP2024534720A (ja) 遺伝子改変細胞を作製するための方法
JP2021521850A (ja) Ｘ連鎖性高ＩｇＭ症候群のゲノム編集治療
WO2023119201A2 (en) Genetically engineered t cells with disrupted casitas b-lineage lymphoma proto-oncogene-b (cblb) and uses thereof
Frost et al. Fluorinated silane-modified filtroporation devices enable gene knockout in human hematopoietic stem and progenitor cells
WO2023133423A1 (en) Modified hematopoietic stem cells and uses thereof
AU2022386233A1 (en) Biomarkers of megakaryocyte-derived extracellular vesicles
EP4574979A1 (en) Engineered immune cell and preparation method therefor
JP2024532305A (ja) 細胞を修飾する方法
Worthington Cellular and Molecular Mechanisms of Hematopoietic Stem Cell Regenerative Capacity Throughout Life
WO2025221789A1 (en) Compositions and methods for use in car/tcr cell therapies
EP4341414A1 (en) Gene therapy for the treatment of severe combined immunodeficiency (scid) related to rag1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200918

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220524

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221220